News

May 19, 2017May 19, 2017

Progenitor Develops 2 New Gene Editing Tools to Improve Off-the-Shelf Cellular Immunotherapies

News

Progenitor Life Sciences, a company that specializes in developing off-the-shelf cellular immunotherapies, has developed two additional technologies that will improve immune cell engineering and production in future immunotherapy approaches. The ... Read more

May 18, 2017May 18, 2017

Vaccines Based on Immunotherapies Being Tested in Phase 2 Trials in Brain Cancer

News

Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating vaccines ... Read more

May 17, 2017

OSE-172 Continues to Show Promising Activity Against Multiple Cancer Models, Researchers Say

News

A new-generation checkpoint inhibitor, OSE-172 (Effi-DEM), targeting myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), can effectively modify the tumor environment and lead to the intra-tumoral accumulation of cytotoxic ... Read more

May 16, 2017

Granzyme B Protein May Help ID Cancer Patients Who Respond to Immunotherapy Treatments

News

Researchers identified a new biomarker that may help them track cancer response to treatment using a noninvasive positron emission tomography (PET) imaging method. The new method measures granzyme B, a ... Read more

May 15, 2017May 15, 2017

NantKwest, NantCell to Test NANT Vaccine in Phase 1/2 Trial for Pancreatic Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has granted investigational new drug status to the NANT cancer vaccine, to be assessed in a Phase 1/2 clinical trial (NCT03136406) for pancreatic ... Read more

May 12, 2017

Tecentriq Fails to Improve Survival in Previously Treated Metastatic Bladder Cancer Patients in Phase 3 Study

News

The immune checkpoint inhibitor Tecentriq (atezolizumab) failed to improve overall survival in a subset of patients with locally advanced or metastatic urothelial cancer (mUC). The findings mean that Genentech‘s Phase ... Read more

May 11, 2017

Inovio, Regeneron Plan Clinical Trial of Triple-Combo Immunotherapy for Brain Tumors

News

Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor will be able to enroll soon in a Phase 1b/2a clinical trial of a triple-combination immunotherapy for the cancer. Inovio Pharmaceuticals will ... Read more

May 10, 2017May 10, 2017

FDA Approves Immune Checkpoint Inhibitor Bavencio for Common Type of Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Bavencio (avelumab) to treat patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-based chemotherapy, or who ... Read more

May 9, 2017May 9, 2017

SU2C’s Online Education Program Releases Training Modules to Prepare Nurses for Immunotherapy Care

News

Stand Up to Cancer (SU2C) has released a new series of training modules to give nurses the skills and knowledge needed in dealing with emerging immunotherapy treatments for cancer patients. Experts from ... Read more

May 8, 2017May 8, 2017

FDA Approves Roche’s PD-L1 Biomarker Test for Urothelial Carcinoma Patients Considered for Imfinzi Therapy

News

The U.S. Food and Drug Administration (FDA) has approved Roche‘s Ventana PD-L1 (SP263) Assay as a complementary diagnostic tool to evaluate PD-L1 status in patients with locally advanced or metastatic ... Read more